Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #367100 on Innovation Pharmaceuticals Inc (IPIX)
Lemoncat
07/26/21 9:53 PM
#367101 RE: Jhawker #367100
Only about 3% of cancer drugs make from trials
Cellceutix Reports Spleen Lesion ‘Disappears’ in Patient with Metastatic Stage 4 Ovarian Cancer in Clinical Trial of Anti-Cancer Drug Kevetrin is pleased to report the near complete disappearance of a metastatic lesion in the spleen of a Stage 4 ovarian cancer patient who was enrolled in the Company’s Phase 1 clinical trial of anti-cancer drug candidate Kevetrin™
Dapto patent cliff was a know thing
In our completed 215-patient Phase 2b trial of Brilacidin ABSSSI, two different single dose treatments of Brilacidin, as well as a three-day regimen, were all shown to be comparably effective as the FDA-approved 7-day dosing regimen of the blockbuster antibiotic daptomycin. In 2014, daptomycin was marketed under that brand name Cubicin by Cubist Pharmaceuticals and generated $1.046 billion in sales. In December 2014, Merck & Co. agreed to acquire Cubist Pharmaceuticals for approximately $9.5 billion, including debt.